The Ministry of Health has issued a stern warning against the off-label use of Semaglutide, popularly known by the brand name Ozempic, for weight loss purposes.
In a statement on Tuesday, August 19, the Pharmacy and Poisons Board (PPB) Chief Executive Officer Fred Siyoi clarified that the drug is strictly approved for the treatment of adults with uncontrolled type 2 diabetes mellitus. The board cautioned that while the medication has become increasingly popular for weight management, particularly among celebrities, unsupervised use could expose individuals to serious health risks.
“Semaglutide is a Prescription-Only Medicine and its unsupervised or off-label use may result in serious health outcomes,” PPB stated. Only licensed healthcare professionals are authorized to prescribe the drug.
Among the common side effects associated with Semaglutide are hypoglycemia (low blood sugar), gastro-oesophageal reflux disease, intestinal obstruction, and eye-related complications. These can range from mild to severe, depending on dosage and individual health factors.
While clinical evidence shows that the benefits of Semaglutide outweigh its risks when used appropriately, PPB expressed concern about its misuse. The board urged the public to report any suspected adverse effects or substandard products through its official reporting channels.
Globally, Semaglutide has gained attention for its additional benefits, including weight reduction and cardiovascular and kidney protection. In Kenya, social media influencers and celebrities have amplified its popularity by showcasing dramatic weight loss results, often portraying it as a quick fix compared to traditional methods like exercise and dietary changes.
However, health experts have warned that excessive or unregulated use can have devastating consequences. Dr. Kenneth Blum, a professor at Western University Health Sciences and Ariel University, emphasized that overuse of GLP1 receptor agonists like Semaglutide could also trigger mental health risks and mood disorders.
“This study should not be ignored, despite the hype surrounding the positive clinical outcomes of GLP1 receptor agonists. We urge the clinical prescribing community to proceed with caution to avoid another tragic wave of ‘people dying to lose weight,’” Dr. Blum noted.
The Ministry has reaffirmed that the drug should only be used under strict medical guidance, reiterating that off-label consumption poses significant dangers to public health.
